MGTA 456

Drug Profile

MGTA 456

Alternative Names: Cord blood stem cell therapy - Novartis; Expanded umbilical cord blood - Novartis; HSC-835; LFU835 expanded umbilical cord blood stem cells; MGTA-456; Spanlecortemlocel

Latest Information Update: 22 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer Magenta Therapeutics
  • Class Stem cell therapies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Haematological malignancies
  • Clinical Phase Unknown Transplant rejection

Most Recent Events

  • 12 Dec 2017 Safety and efficacy data from a phase II expansion trial in Hematological malignancies presented at the 59th annual meeting of the American Society of Hematology (ASH-2017)
  • 12 Dec 2017 Phase-II clinical trials in Haematological malignancies in USA (IV)
  • 06 Oct 2017 Novartis withdraws a phase I/II trial for Mucopolysaccharidosis-I, Metachromatic leukodystrophy, Globoid cell leukodystrophy and Cerebral adrenoleukodystropy (In infants, In children, In adolescents, In adults) in USA, prior to enrolment (Parenteral) (NCT02715505)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top